Despite recent progress in the treatment of NSCLC with the approval of EGFR inhibitors as first-line therapy, resistance to these inhibitors always occurs after a median duration of 9–15 months31, thus necessitating the development of more efficient therapeutics. This evidence concerns the gene EGFR and non-small cell lung carcinoma.